NPC1L1 Knockout Cell Line (A549)

The choice depends on whether you are studying NPC1L1's role as a cholesterol uptake transporter in a non-physiological cellular context (lung cancer cells do not endogenously express NPC1L1 at high levels — the principal sites are intestinal enterocytes and hepatic canalicular membrane). The Knockout line is appropriate when studying NPC1L1 in this non-physiological context — for example, as a clean genetic background for studying ezetimibe pharmacology in heterologous expression contexts. Overexpression studies of NPC1L1 in A-549 may be more informative than knockout given the limited endogenous NPC1L1 expression in lung cancer cells. Important consideration: A-549 is not a physiologically relevant context for NPC1L1 function. The EDITGENE NPC1L1 Knockout in A-549 is most useful for biochemistry, antibody specificity testing, or as a defined null background for heterologous NPC1L1 expression studies. For physiologically relevant NPC1L1 research, the parallel NPC1L1 Knockout in Huh-7 (also available, hepatocellular context) is the recommended product — Huh-7's hepatocellular origin matches NPC1L1's biliary canalicular expression context. Rescue with wild-type or transport-deficient NPC1L1 enables structure-function studies.

Primary applications: • Heterologous NPC1L1 expression studies: clean genetic background for re-expressing wild-type or mutant NPC1L1 for structure-function studies. • Ezetimibe specificity validation: A-549 is not the physiological context but can serve as a defined negative background for ezetimibe specificity testing. • Antibody validation: critical negative control for anti-NPC1L1 antibody validation. • Comparison with Huh-7 NPC1L1 KO: assessment of context-specific NPC1L1 functions between hepatocellular (Huh-7) and lung cancer (A-549) backgrounds. EDITGENE recommends the parallel NPC1L1 Knockout in Huh-7 (also available) as the physiologically relevant model for NPC1L1 research; the A-549 KO is most useful for specific biochemistry applications.

Yes, with the consideration that A-549 is not the physiological context: • Construct design: use a codon-modified NPC1L1 sequence with a small intracellular C-terminal tag (FLAG, HA). NPC1L1 has 13 transmembrane domains with a sterol-sensing domain (SSD) — preserve membrane topology. • Surface localization validation: confirm plasma membrane localization by cell surface staining; physiological apical/canalicular targeting may not occur in non-polarized A-549. • Transport-deficient rescue: SSD or sterol-binding pocket mutations abolish cholesterol uptake. • Functional readout: rescue should restore cellular cholesterol uptake and ezetimibe sensitivity, though baseline activities may be lower than in hepatocellular contexts. A-549 transduces efficiently with lentivirus and supports stable rescue line generation.